ContraFect Management
Management criteria checks 2/4
ContraFect's CEO is Roger Pomerantz, appointed in Apr 2019, has a tenure of 4.08 years. total yearly compensation is $2.23M, comprised of 31.5% salary and 68.5% bonuses, including company stock and options. directly owns 0% of the company’s shares, worth €1.30. The average tenure of the management team and the board of directors is 4.1 years and 9.1 years respectively.
Key information
Roger Pomerantz
Chief executive officer
US$2.2m
Total compensation
| CEO salary percentage | 31.5% |
| CEO tenure | 4.1yrs |
| CEO ownership | 0.00006% |
| Management average tenure | 4.1yrs |
| Board average tenure | 9.1yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2022 | US$2m | US$702k | -US$65m |
| Sep 30 2022 | n/a | n/a | -US$60m |
| Jun 30 2022 | n/a | n/a | -US$48m |
| Mar 31 2022 | n/a | n/a | -US$35m |
| Dec 31 2021 | US$2m | US$666k | -US$20m |
| Sep 30 2021 | n/a | n/a | -US$22m |
| Jun 30 2021 | n/a | n/a | -US$14m |
| Mar 31 2021 | n/a | n/a | -US$26m |
| Dec 31 2020 | US$4m | US$605k | -US$28m |
| Sep 30 2020 | n/a | n/a | -US$32m |
| Jun 30 2020 | n/a | n/a | -US$41m |
| Mar 31 2020 | n/a | n/a | -US$32m |
| Dec 31 2019 | US$2m | US$413k | -US$13m |
| Sep 30 2019 | n/a | n/a | US$3m |
| Jun 30 2019 | n/a | n/a | US$4m |
| Mar 31 2019 | n/a | n/a | -US$7m |
| Dec 31 2018 | US$90k | n/a | -US$38m |
| Sep 30 2018 | n/a | n/a | -US$48m |
| Jun 30 2018 | n/a | n/a | -US$46m |
| Mar 31 2018 | n/a | n/a | -US$28m |
| Dec 31 2017 | US$89k | n/a | -US$16m |
| Sep 30 2017 | n/a | n/a | -US$10m |
| Jun 30 2017 | n/a | n/a | -US$19m |
| Mar 31 2017 | n/a | n/a | -US$26m |
| Dec 31 2016 | US$97k | n/a | -US$29m |
Compensation vs Market: Roger's total compensation ($USD2.23M) is above average for companies of similar size in the German market ($USD418.12K).
Compensation vs Earnings: Roger's compensation has increased whilst the company is unprofitable.
CEO
Roger Pomerantz (65 yo)
4.1yrs
Tenure
US$2,225,482
Compensation
Dr. Roger James Pomerantz, M.D., F.A.C.P., serves as Director at X-Vax Technology, Inc. He serves as an Independent Vice Chairman of the Board of Enlivex Therapeutics Ltd. since May 2022. He is Independent...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 4.1yrs | US$2.23m | 0.000060% € 1.3 | |
| Chief Financial Officer | 4.5yrs | US$957.21k | 0.0015% € 31.8 | |
| General Counsel | 8.8yrs | US$844.90k | 0.000060% € 1.3 | |
| Vice President of Human Resources | 1.2yrs | no data | no data | |
| Senior Vice President of Translational Sciences & Preclinical Development | 1.9yrs | no data | no data |
4.1yrs
Average Tenure
59yo
Average Age
Experienced Management: 22R's management team is considered experienced (4.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 9.1yrs | US$2.23m | 0.000060% € 1.3 | |
| Lead Independent Director | 12.1yrs | US$176.04k | 0.065% € 1.4k | |
| Vice Chairman | 8yrs | US$160.54k | 0.0017% € 35.9 | |
| Independent Director | 2.9yrs | US$150.54k | 0% € 0 | |
| Independent Director | 9.1yrs | US$160.04k | 0.00064% € 13.9 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Chairman of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 13yrs | US$155.54k | 0.0049% € 106.5 | |
| Independent Director | 9.1yrs | US$165.04k | 0.030% € 640.0 | |
| Member of Scientific Advisory Board | no data | no data | no data |
9.1yrs
Average Tenure
69yo
Average Age
Experienced Board: 22R's board of directors are considered experienced (9.1 years average tenure).